Rigetti Computing’s surge as a quantum-computing pure play has spawned a highly aggressive ETF niche built around the stock’s daily swings. With RGTI trading near $16.50 and carrying a beta of 4.01, the launch of leveraged single-stock funds has turned an already volatile equity into an even sharper tactical instrument.
The most closely watched product is the Defiance Daily Target 2X Long RGTI ETF, ticker RGTX, which began trading on March 31, 2025. Alongside Tradr’s 2X long RGTU and Defiance’s inverse RGTZ, the lineup gives traders amplified exposure to Rigetti’s moves in either direction, while also raising the risk of rapid losses and performance decay.
For investors following the quantum-computing trade, the RGTI leveraged ETFs are more than a product launch. They are a sign that speculative interest around early-stage quantum names has grown strong enough to support exchange-traded vehicles designed for short-term directional bets.
Key Facts
- RGTI was trading near $16.50, while Rigetti’s market capitalization stood at roughly $5.5 billion.
- Rigetti’s stock carries a beta of 4.01 and daily volatility of about 5.74%, making it one of the market’s more unstable individual equities.
- RGTX launched on March 31, 2025, seeking 200% of Rigetti’s daily percentage move, while RGTZ targets -200% of the daily move.
- Rigetti reported about $7.09 million in full-year 2025 revenue, down 34.31% from $10.79 million a year earlier.
- The company ended the first quarter of 2026 with $569.0 million in cash, equivalents, and investments and no debt.
RGTI leveraged ETFs
The central issue with RGTI leveraged ETFs is simple: they magnify a stock that is already defined by extreme swings. Rigetti trades on a mix of early-stage technology promise, government policy support, and speculative sentiment around quantum computing. That combination can produce large one-day moves in the underlying shares, and a 2x structure can turn those into gains or losses exceeding 15% in a single session.
These products are built for daily exposure, not long-term ownership. The long funds, including RGTX and RGTU, aim to deliver twice Rigetti’s percentage change for one trading day. The inverse fund, RGTZ, seeks to provide the opposite of twice the daily move. Because the exposure resets every day, returns over longer holding periods can diverge sharply from a simple expectation of “double the stock.”
That matters because Rigetti is not a stable, cash-generating technology company. It is an early-stage quantum hardware business with a small revenue base, large losses, and a valuation that depends heavily on future commercialization. Traders may see these ETFs as a way to express a view on quantum momentum, but traditional investors should recognize that the products are tied to one of the most speculative segments in public markets.
Leveraged exposure to Rigetti is not just a higher-conviction trade on quantum computing; it is a bet that volatility, timing, and market sentiment will all break in the right direction over a very short window.
Why the daily reset changes the outcome
The most misunderstood feature of single-stock leveraged ETFs is the daily reset mechanism. Funds such as RGTX typically use swaps and other derivatives to create 200% notional exposure to Rigetti’s one-day move. At the close of each session, that exposure is rebalanced to maintain the target leverage for the next day.
This structure can erode returns in volatile sideways trading. If Rigetti rises 10% one day and falls 10% the next, the stock is down only 1% cumulatively. A 2x daily fund would rise 20% and then fall 20%, leaving it down 4%. In a stock with average daily volatility near 5.74%, that compounding effect can become significant quickly, especially over several sessions of back-and-forth trading.
Implications for Investors
For active traders, the RGTI leveraged ETFs create a more direct way to capitalize on catalysts in the quantum sector. Those catalysts include federal support for domestic quantum development, executive actions that elevate the technology’s strategic profile, and company-specific milestones such as Rigetti’s 108-qubit Cepheus-1-108Q system and on-premises Novera QPU shipments. If Rigetti breaks above technical resistance around $22 and then $27.79, leveraged long funds could react sharply.
For longer-term investors, the bigger takeaway is caution. Rigetti generated only about $7 million in annual revenue in 2025, even as its valuation approached $5.5 billion. Losses widened to $216.21 million, underscoring how early the business remains in its commercial development. The company’s $569.0 million cash position gives it time to execute, but the gap between current fundamentals and market expectations is wide, and that gap is a major driver of the stock’s volatility.
Investors should also watch dilution risk and policy sensitivity. Rigetti’s valuation has been supported in part by enthusiasm for government-backed quantum investment and strategic national interest in the sector. That can be a powerful tailwind, but sentiment can reverse if funding expectations cool, commercialization timelines slip, or broader risk appetite weakens. In that environment, inverse products such as RGTZ may attract short-term attention, but they carry the same path-dependent risks as the long funds.
The broader lesson is that these ETFs are trading tools rather than portfolio building blocks. They may suit highly experienced market participants with defined time horizons, strict risk controls, and constant monitoring. For most investors, owning a daily-reset leveraged product tied to a pre-commercial quantum stock introduces a level of complexity and volatility that is difficult to justify.
Rigetti remains one of the market’s clearest pure-play quantum stories, and that alone may keep interest elevated. But as the RGTI leveraged ETFs gain attention, the next phase will depend less on product novelty and more on whether Rigetti can convert policy support and technical progress into durable revenue growth.